menu
    • menu
    [{"orgOrder":0,"company":"Axonis Therapeutics","sponsor":"Kerry Murphy","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Large molecule","year":"2020","type":"Financing","leadProduct":"KCC2","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Discovery","graph3":"Axonis Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Axonis Therapeutics \/ Kerry Murphy","highestDevelopmentStatusID":"2","companyTruncated":"Axonis Therapeutics \/ Kerry Murphy"},{"orgOrder":0,"company":"Mediar Therapeutics","sponsor":"Distributed Bio","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"Neutralizing antibodies","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Discovery","graph3":"Mediar Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Mediar Therapeutics \/ Distributed Bio","highestDevelopmentStatusID":"2","companyTruncated":"Mediar Therapeutics \/ Distributed Bio"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Aravive","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Bispecific antibodies","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Discovery","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Biologics \/ Aravive","highestDevelopmentStatusID":"2","companyTruncated":"WuXi Biologics \/ Aravive"},{"orgOrder":0,"company":"UMass Dartmouth","sponsor":"CaaMTech","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Expanded Collaboration","leadProduct":"Tryptamine","moa":"5-HT2A receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Discovery","graph3":"UMass Dartmouth","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"UMass Dartmouth \/ CaaMTech","highestDevelopmentStatusID":"2","companyTruncated":"UMass Dartmouth \/ CaaMTech"},{"orgOrder":0,"company":"EuMentis Therapeutics","sponsor":"DOD","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Discovery","graph3":"EuMentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"EuMentis Therapeutics \/ DOD","highestDevelopmentStatusID":"2","companyTruncated":"EuMentis Therapeutics \/ DOD"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Enveric Biosciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Enveric Biosciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EV102

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Discovery

                            Sponsor : Akos Biosciences

                            Deal Size : $61.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement

                            Details : Under the terms of the licensing agreement, Aries will gain the rights to Enveric’s patented topical product EV102 for the clinical development of radiation dermatitis treatment.

                            Brand Name : EV102

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 15, 2024

                            Lead Product(s) : EV102

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Discovery

                            Sponsor : Akos Biosciences

                            Deal Size : $61.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            EuMentis Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            EuMentis Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Discovery

                            Sponsor : DOD

                            Deal Size : $3.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            EuMentis Therapeutics Inc. Receives $3 Million Award from United States Department of Defense (DoD) to Advance...

                            Details : Under the DoD award, EuMentis will conduct preclinical TBI studies in validated large animal model in collaboration with Dr. Todd Killbaugh at the Children’s Hospital of Philadelphia and plans to advance its lead NMDA receptor antagonist candidate for ...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 08, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Discovery

                            Sponsor : DOD

                            Deal Size : $3.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            UMass Dartmouth

                            Country arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            UMass Dartmouth

                            Country arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tryptamine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Discovery

                            Sponsor : CaaMTech

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            CaaMTech Expands Successful Next-Gen Drug Research Collaboration with UMass Dartmouth

                            Details : The renewal and expansion of this collaboration recognizes the success of Associate Professor of Chemistry & Biochemistry Dr. David R. Manke and his associated team of researchers in the synthesis and crystallography of novel tryptamines.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 09, 2020

                            Lead Product(s) : Tryptamine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Discovery

                            Sponsor : CaaMTech

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Mediar Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Mediar Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neutralizing antibodies

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Discovery

                            Sponsor : Distributed Bio

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Distributed Bio Partners With Mediar Therapeutics, Inc.

                            Details : Under the terms of this partnership, Distributed Bio will use its SuperHuman2.0 Antibody Discovery platform to identify lead antibodies for Mediar programs.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 03, 2020

                            Lead Product(s) : Neutralizing antibodies

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Discovery

                            Sponsor : Distributed Bio

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Axonis Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Axonis Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KCC2

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Discovery

                            Sponsor : Kerry Murphy

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            AXONIS Therapeutics, Inc. Announces Seed Financing for Preclinical Development of Neuromodulating KCC2 Therapy

                            Details : The funds will enable AXONIS to conduct pre-clinical studies on its novel technology that reactivates spared neural tissue at the spinal cord injury site through upmodulation of the KCC2 protein activity.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 28, 2020

                            Lead Product(s) : KCC2

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Discovery

                            Sponsor : Kerry Murphy

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            WuXi Biologics

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            WuXi Biologics

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bispecific antibodies

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Discovery

                            Sponsor : Aravive

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            WuXi Biologics and Aravive Collaborate to Develop Novel Antibodies Targeting Cancer and Fibrosis Using the WuX...

                            Details : Collaboration grants Aravive the right to use the proprietary WuXiBody™ platform to develop high-affinity bispecific antibodies for a target implicated in cancer and fibrosis.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 30, 2020

                            Lead Product(s) : Bispecific antibodies

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Discovery

                            Sponsor : Aravive

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth